ECSP21078309A - Glicoproteínas sialiladas - Google Patents

Glicoproteínas sialiladas

Info

Publication number
ECSP21078309A
ECSP21078309A ECSENADI202178309A ECDI202178309A ECSP21078309A EC SP21078309 A ECSP21078309 A EC SP21078309A EC SENADI202178309 A ECSENADI202178309 A EC SENADI202178309A EC DI202178309 A ECDI202178309 A EC DI202178309A EC SP21078309 A ECSP21078309 A EC SP21078309A
Authority
EC
Ecuador
Prior art keywords
shear stress
sialilated
glycoproteins
stable
pharmaceutical
Prior art date
Application number
ECSENADI202178309A
Other languages
English (en)
Inventor
Siddhesh Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP21078309A publication Critical patent/ECSP21078309A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se describen preparaciones farmacéuticas que contienen inmunoglobulinas hipersialiladas. Las preparaciones son estables al esfuerzo de cizalla. Las composiciones farmacéuticas descritas en la presente descripción proporcionan composiciones de hsIgG farmacéuticamente aceptables que son estables contra el esfuerzo de cizalla (p. ej., no se forman un número significativo de partículas subvisibles cuando la formulación se somete a esfuerzo de cizalla, tal como agitación, por ejemplo, durante el envío) y, por lo tanto, pueden enviarse y manipularse en forma líquida.
ECSENADI202178309A 2019-04-18 2021-10-22 Glicoproteínas sialiladas ECSP21078309A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18

Publications (1)

Publication Number Publication Date
ECSP21078309A true ECSP21078309A (es) 2021-11-30

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202178309A ECSP21078309A (es) 2019-04-18 2021-10-22 Glicoproteínas sialiladas

Country Status (20)

Country Link
US (1) US20220211849A1 (es)
EP (1) EP3955962A4 (es)
JP (1) JP2022529168A (es)
KR (1) KR20220002963A (es)
CN (1) CN113795275A (es)
AU (1) AU2020259492A1 (es)
BR (1) BR112021020509A8 (es)
CA (1) CA3137101A1 (es)
CL (1) CL2021002668A1 (es)
CO (1) CO2021013926A2 (es)
CR (1) CR20210521A (es)
EA (1) EA202192860A1 (es)
EC (1) ECSP21078309A (es)
IL (1) IL287306A (es)
JO (1) JOP20210281A1 (es)
MX (1) MX2021012710A (es)
PE (1) PE20220383A1 (es)
SG (1) SG11202110942SA (es)
WO (1) WO2020215021A1 (es)
ZA (1) ZA202109184B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
US20230417762A1 (en) 2020-11-20 2023-12-28 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248155B2 (en) * 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP3708581A3 (en) * 2009-05-27 2021-10-20 Takeda Pharmaceutical Company Limited A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
US20160108450A1 (en) * 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
CA2908407C (en) * 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
WO2018131893A1 (ko) * 2017-01-11 2018-07-19 ㈜셀트리온 안정한 액체 제제

Also Published As

Publication number Publication date
JOP20210281A1 (ar) 2023-01-30
BR112021020509A2 (pt) 2022-03-15
CR20210521A (es) 2022-04-01
EA202192860A1 (ru) 2021-12-23
PE20220383A1 (es) 2022-03-18
WO2020215021A1 (en) 2020-10-22
CL2021002668A1 (es) 2022-05-27
CN113795275A (zh) 2021-12-14
BR112021020509A8 (pt) 2023-01-10
US20220211849A1 (en) 2022-07-07
SG11202110942SA (en) 2021-11-29
EP3955962A1 (en) 2022-02-23
JP2022529168A (ja) 2022-06-17
KR20220002963A (ko) 2022-01-07
MX2021012710A (es) 2021-11-12
ZA202109184B (en) 2023-04-26
EP3955962A4 (en) 2022-12-14
AU2020259492A1 (en) 2021-11-11
CA3137101A1 (en) 2020-10-22
IL287306A (en) 2021-12-01
CO2021013926A2 (es) 2021-10-29

Similar Documents

Publication Publication Date Title
ECSP21078309A (es) Glicoproteínas sialiladas
AR111455A1 (es) Formulación estable de anticuerpo
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
BR112018008880A2 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
MX2017012877A (es) Composiciones gomosas de multicomponentes con nucleo suave.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
BR112021006598A2 (pt) composição farmacêutica líquida, e, kit
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
MX2022013566A (es) Anticuerpo.
BR112022001330A2 (pt) Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
CO2018012502A2 (es) Formulaciones y métodos para el tratamiento de organismos fotosintéticos y la mejora de las calidades y cantidades de rendimientos con formulaciones de compuestos de glicano
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
MX2022006130A (es) Composiciones inyectables de ácido ursodeoxicólico.
CO2020013552A2 (es) Formulación de anticuerpos
MX2023000348A (es) Composicion que contiene ciclodextrina y busulfan.
BR112018074143A2 (pt) composição tópica estável e método de tratamento de infecções fúngicas
CO2021016879A2 (es) Formulaciones estabilizadas de ditiocarbamatos
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
BR102020012866A8 (pt) Composições tópicas contendo derivados de n-acil-dipeptídeo e ácido glicólico
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient
CO2021000763A2 (es) Estabilidad de la vitamina d en b-hidroxi- b-metilbutirato(hmb)